Since current therapies are ineffective against the expression of Syntenin-1 and SDC-1 in RA synovial tissue and blood, targeting this pathway and its interconnected metabolic intermediates may provide a new therapeutic strategy. This evidence concerns the gene SDCBP and rheumatoid arthritis.